Hepatitis C Treatment in Probation and Parole Office

Jens Rosenau

Status

Completed

Conditions

Hepatitis C

HCV

Treatments

Behavioral: Telehealth in Parole/Probation Office

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT05413785

IMDDN-22-HEP-C-TX

Details and patient eligibility

About

This prospective cohort study compares aims to determine the efficacy and effectiveness of telemedicine-supported on-site linkage to care and treatment in a community probation and parole office (P&P office) setting and compare the results with a historic control with referral to care. Research participants will be followed in the P&P office when they report to their officer during regularly scheduled appointments. Participants will receive treatment without having to travel to a specialist's office. The telemedicine visit will include a consultation with an experienced HCV provider such as a hepatologist or an advanced practice provider and a specialty pharmacist who will educate about and monitor HCV treatment. The UK specialty pharmacy will be available to participants and the HCV management team through a 24-hour support line. Participants will be treated per HCV guidelines and insurance preference.

Enrollment

77 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clients who will be supervised in the probation and parole office for at least 5 months
History of hepatitis C
Able to obtain health insurance
Capacity to provide written, informed consent
Life expectancy >1 year

Exclusion criteria

Negative HCV RNA
Pregnant or breast-feeding
HIV or HBV co-infection
Liver cirrhosis with Child-Turcotte-Pugh score 6 or greater at baseline lab work
Subjects with impaired capacity to provide informed consent